<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03280979</url>
  </required_header>
  <id_info>
    <org_study_id>RR&amp;HDMPGTN</org_study_id>
    <nct_id>NCT03280979</nct_id>
  </id_info>
  <brief_title>Rescue Regimen and High Dose Methotrexate in Management of Presistent Gestational Trophoplastic Neoplasia</brief_title>
  <official_title>Comparison Between Rescue Regimen and High Dose Methotrexate in the Managment of Presistent Gestational Trophoplastic Neoplasia :( A Randomized Controlled Trial )</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gestational trophoblastic neoplasia (GTN) are malignant lesions that arise from abnormal&#xD;
      proliferation of placental trophoblast. The pathologic conditions that make up this entity&#xD;
      include invasive partial and complete hydatidiform mole, choriocarcinoma, placental site&#xD;
      trophoblastic tumor (PSTT), and epithelioid trophoblastic tumor (ETT). GTN often arises after&#xD;
      molar pregnancies but can also occur after any gestation including miscarriages and term&#xD;
      pregnancies. In the United States, hydatidiform moles are observed in approximately 1/600&#xD;
      therapeutic abortions and 1/1000-2000 pregnancies . Most cases of GTN are diagnosed when the&#xD;
      serum hCG levels plateau or rise in patients being observed after the diagnosis of&#xD;
      hydatidiform mole.These malignancies are highly susceptible to chemotherapy and it is often&#xD;
      possible to achieve cure while preserving the woman's reproductive function&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      When reporting GTN data, it is useful to use both the FIGO anatomic staging system and&#xD;
      prognostic scoring system . A FIGO score of 6 or less indicates low-risk GTN whereas a score&#xD;
      of 7 or more identifies high-risk disease.&#xD;
&#xD;
      Table 1- FIGO Anatomical staging of gestational trophoblastic neoplasia:&#xD;
&#xD;
      Stage I Disease confined to the uterus Stage II Disease extends to the outside of the uterus,&#xD;
      but is limited to the genital structures Stage III Disease extends to the lungs, with or&#xD;
      without genital tract involvement Stage IV All other metastatic sites&#xD;
&#xD;
      Table 2- FIGO Scoring system:&#xD;
&#xD;
      FIGO SCORING 0 1 2 4 Age (years) Antecedent pregnancy Interval months from end of index&#xD;
      pregnancy to treatment Pretreatment serum hCG (iu/l) Largest tumour size, including uterus&#xD;
      Site of metastases Number of metastases Previous failed chemotherapy &lt;40 ≥40 - - mole&#xD;
      abortion term &lt;4 4-6 7-12 &gt;12 &lt;1000 1000-10000 10000-100000 &gt;100000 &lt;3cm 3-4cm ≥5 - Lung&#xD;
      spleen&amp;kidney GIT liver&amp;brain&#xD;
&#xD;
        -  1-4 5-8 &gt;8&#xD;
&#xD;
        -  - 1 drug 2 or more drugs&#xD;
&#xD;
      RCOG guidelines (No. 38February 2010 ) recommends the use of rescue regimen of alternating&#xD;
      methotrexate( MTX) and leucoverin for 8 days (class D). However, several protocols using MTX&#xD;
      were described. No prospective randomised controlled trials have been done to compare the&#xD;
      efficacy of resue regimen with the ther protocols. In a retrospective study done showed that&#xD;
      high dose methotrexate regimen is more effective than the rescue regimen.&#xD;
&#xD;
      In addition, several concerns have been raised towards the use of leucoverin with&#xD;
      methotrexate, although reducing the side effects, however, it may increase the resistence to&#xD;
      the effect of MTX .&#xD;
&#xD;
      On the other hand, High dose regimen offers a less hospital stay which may be more convenient&#xD;
      to the patients, together with the same incidence of side effects.&#xD;
&#xD;
      In our study we are going to compare the efficacy and tolerance of both regimens in patients&#xD;
      diagnosed to have low risk PGTN.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">October 2017</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cure rate</measure>
    <time_frame>12 month</time_frame>
    <description>cure rate till B hcG is negative and then 2 consolidation regimens</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>decline in Bhcg</measure>
    <time_frame>12 month</time_frame>
    <description>Number of cycles for decline in BhCG</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Gestational Trophoblastic Disease</condition>
  <arm_group>
    <arm_group_label>study group1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the rescue regimen , we administer MTX in an eight-day treatment regimen consisting of four administrations of MTX given at 1 mg/kg I.M. every other day with folinic acid 0.1 mg/kg I.M,. given on intervening days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>study group2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the high dose MTX protocol, the patients will receive 100 mg/m2 intravenous (IV) MTX bolus followed by 200 mg/m2IV MTX infused over 12 hours followed by folinic acid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rescue regimen</intervention_name>
    <description>In the rescue regimen , we administer MTX in an eight-day treatment regimen consisting of four administrations of TX given at 1 mg/kg I.M. every other day with folinic acid 0.1 mg/kg I.M,. given on intervening days.</description>
    <arm_group_label>study group1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>high dose methotrxate</intervention_name>
    <description>In the high dose MTX protocol, the patients will receive 100 mg/m2 intravenous (IV) MTX bolus followed by 200 mg/m2IV MTX infused over 12 hours followed by folinic acid</description>
    <arm_group_label>study group2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 18-50&#xD;
&#xD;
          -  BW: 50-100 kg&#xD;
&#xD;
          -  willing and consenting to be enrolled in the study&#xD;
&#xD;
          -  Absence of active vaginal bleeding which requires surgical intervention • - WHO score&#xD;
             &lt;6&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Renal and liver dysfunction or blood dyscariasis&#xD;
&#xD;
          -  high risk persistent gestational trophoblastic disease.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>zahraa magdy, md</last_name>
    <phone>01002603379</phone>
    <email>zahraamagdy92@yahoo.com</email>
  </overall_contact>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>September 11, 2017</study_first_submitted>
  <study_first_submitted_qc>September 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2017</study_first_posted>
  <last_update_submitted>September 11, 2017</last_update_submitted>
  <last_update_submitted_qc>September 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Zahraa Magdy</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gestational Trophoblastic Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

